09.09.14
ProBioGen AG, based in Berlin, Germany, is investing €20 million to expand operations and plans to double its workforce.
ProBioGen develops novel processes for the production of biopharmaceutical drug substances, with services ranges from cell line and process development to GMP contract manufacturing. The company also develops technologies to improve bioactive substances and has created a portfolio of proprietary rights for optimized biopharmaceutical manufacturing.
ProBioGen was recently granted licenses with several global pharma companies, including Boehringer Ingelheim and Novartis. The company also plans to further exploit its internal potential for the development of production cell lines, process engineering and GMP manufacture of biopharmaceuticals.
"Together with our parent company, we will continue to expand and invest in Berlin," said Dr. Wieland Wolf chief executive officer of ProBioGen. "With an investment of around 20 million euros, we will strengthen our market position, add two additional disposable 1000L bioreactors and, within the next two years, will double our staff from currently 75 highly skilled and dedicated employees" says the CEO about ProBioGen's further growth.
ProBioGen develops novel processes for the production of biopharmaceutical drug substances, with services ranges from cell line and process development to GMP contract manufacturing. The company also develops technologies to improve bioactive substances and has created a portfolio of proprietary rights for optimized biopharmaceutical manufacturing.
ProBioGen was recently granted licenses with several global pharma companies, including Boehringer Ingelheim and Novartis. The company also plans to further exploit its internal potential for the development of production cell lines, process engineering and GMP manufacture of biopharmaceuticals.
"Together with our parent company, we will continue to expand and invest in Berlin," said Dr. Wieland Wolf chief executive officer of ProBioGen. "With an investment of around 20 million euros, we will strengthen our market position, add two additional disposable 1000L bioreactors and, within the next two years, will double our staff from currently 75 highly skilled and dedicated employees" says the CEO about ProBioGen's further growth.